APA (7th ed.) Citation

Tenshin, H., Teramachi, J., Ashtar, M., Hiasa, M., Inoue, Y., Oda, A., . . . Abe, M. (2022). TGF‐β‐activated kinase‐1 inhibitor LL‐Z1640‐2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF‐α and RANKL expression. Clinical & translational immunology, 11(1), e1371-n/a. https://doi.org/10.1002/cti2.1371

Chicago Style (17th ed.) Citation

Tenshin, Hirofumi, et al. "TGF‐β‐activated Kinase‐1 Inhibitor LL‐Z1640‐2 Reduces Joint Inflammation and Bone Destruction in Mouse Models of Rheumatoid Arthritis by Inhibiting NLRP3 Inflammasome, TACE, TNF‐α and RANKL Expression." Clinical & Translational Immunology 11, no. 1 (2022): e1371-n/a. https://doi.org/10.1002/cti2.1371.

MLA (9th ed.) Citation

Tenshin, Hirofumi, et al. "TGF‐β‐activated Kinase‐1 Inhibitor LL‐Z1640‐2 Reduces Joint Inflammation and Bone Destruction in Mouse Models of Rheumatoid Arthritis by Inhibiting NLRP3 Inflammasome, TACE, TNF‐α and RANKL Expression." Clinical & Translational Immunology, vol. 11, no. 1, 2022, pp. e1371-n/a, https://doi.org/10.1002/cti2.1371.